A genetic disease affecting the digestive and respiratory functions, cystic fibrosis disrupts the daily lives of patients and their families. Thanks to research, a patient’s life expectancy has significantly increased. Good news for those who have it, two new treatments will be reimbursed at 100%.
Reimbursement of two cystic fibrosis treatments
Good news for patients with cystic fibrosis: two drugs will be reimbursed at 100% by the Social Security. These are Kaftrio and Symkevi, treatments manufactured by the American laboratory Vertex Pharmaceuticals. According to a statement, “ An agreement on the price has just been reached “And” reimbursement of these drugs will occur in the next few days “. Ultimately, 5,000 eligible patients will be able to benefit from it.
During his meeting with several patient associations, the Minister of Solidarity and Health, Olivier Véran, said: “ This agreement on the price of two new pharmaceutical specialties is a tremendous source of hope for patients. This means very concretely that patients will benefit from innovative and effective treatments, giving them the best chances of quality of life and increased life expectancy “.
Cystic fibrosis, a genetic disease that shortens life expectancy
“ Today a child is born every three days with cystic fibrosis and the disease still disrupts the daily lives of many families and victims. The arrival of innovative treatments is therefore a real hope. “, We read in the press release. Of genetic origin, cystic fibrosis is a fatal disease. However, “ thanks to research and improved care, the average life expectancy of a patient is between 40 and 50 years, whereas it was only 5 years in the 1960s », Says Inserm.
As a reminder, cystic fibrosis mainly affects digestive and respiratory functions. It is linked to the alteration of the CFTR gene (cystic fibrosis transmembrane conductance regulator). It first causes a chronic cough, as well as discomfort and a decrease in respiratory function, then, ultimately, respiratory failure.